专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明公开

EP3150577A1 PHENYL DERIVATIVE 失效
标题翻译：苯基衍生物
公开(公告)号：EP3150577A1
公开(公告)日：2017-04-05
申请号：EP16002350.3
申请日：2012-09-27
申请人： ONO PHARMACEUTICAL CO., LTD.
发明人： Naganawa, Atsushi , Kusumi, Kensuke , Otsuki, Kazuhiro , Sekiguchi, Tetsuya , Kakuuchi, Akito , Shinozaki, Koji , Yamamoto, Hiroshi , Nonaka, Shigeyuki
IPC分类号： C07D205/04 , A61K31/397 , A61K31/40 , A61K31/445 , A61K31/4523 , A61K31/453 , A61K31/454 , A61K31/4545 , A61K31/5377 , A61P9/00 , A61P9/06 , A61P9/10 , A61P9/12 , A61P9/14 , A61P11/00 , A61P25/00 , A61P43/00 , C07D207/10 , C07D207/12 , C07D211/48
CPC分类号： A61K31/445 , A61K31/397 , A61K31/40 , A61K31/4523 , A61K31/453 , A61K31/454 , A61K31/4545 , C07D205/04 , C07D207/12 , C07D207/16 , C07D211/48 , C07D211/52 , C07D401/12 , C07D405/12
摘要： The compound represented by the formula (I-1):

wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P 2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P 2 -mediated diseases such as diseases resulting from vascular constriction, fibrosis and respiratory diseases.

22. 发明公开

EP3022176A4 AZACYCLIC CONSTRAINED ANALOGS OF FTY720 有权转让
标题翻译： EINESCHRÄNKTEAZACYCLISCHE ANALOGA VON FTY720
公开(公告)号：EP3022176A4
公开(公告)日：2017-04-05
申请号：EP14825876
申请日：2014-07-15
申请人： UNIV CALIFORNIA
发明人： EDINGER AIMEE , HANESSIAN STEPHEN
IPC分类号： C07D207/12 , A61K31/40 , A61P35/02 , C07F9/572
CPC分类号： C07D207/12 , C07F9/572 , C07F9/5722
摘要： Small molecules comprised of azacyclic constrained analogs of FTY720 are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, leukemia, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.
摘要翻译：提供由FTY720的氮杂受限类似物组成的小分子。还提供了用于治疗疾病，例如白血病和其它疾病的制剂和药物。还提供治疗剂，其含有治疗有效剂量的一种或多种小分子化合物，其以药物有效盐或纯形式存在，包括但不限于用于口服，静脉内或肌内给药的制剂。

23. 发明授权

EP2903982B1 NEW PYRROLIDINE DERIVATIVES AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS 有权
标题翻译：新吡咯烷衍生物及其作为乙酰辅酶A羧化酶抑制剂
公开(公告)号：EP2903982B1
公开(公告)日：2016-12-28
申请号：EP13771485.3
申请日：2013-10-02
申请人： Boehringer Ingelheim International GmbH
发明人： FLECK, Martin , HEIMANN, Annekatrin , HEINE, Niklas , NOSSE, Bernd , ROTH, Gerald Juergen
IPC分类号： C07D403/12 , C07D401/12 , C07D405/04 , C07D405/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D487/04 , C07D207/12 , C07D207/28 , A61K31/41 , A61P3/04 , A61P3/10
CPC分类号： C07D207/12 , C07D207/28 , C07D401/12 , C07D403/12 , C07D405/04 , C07D405/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D487/04

24. 发明授权

EP2417106B1 PROCESS FOR PREPARING PYRROLIDINIUM SALTS 有权
标题翻译：制备吡咯烷鎓盐的方法
公开(公告)号：EP2417106B1
公开(公告)日：2016-11-30
申请号：EP10713193.0
申请日：2010-04-07
申请人： Novartis AG
发明人： ALLMENDINGER, Thomas
IPC分类号： C07D207/12 , C07D233/60 , A61K9/14 , A61K31/40
CPC分类号： C07D207/12 , A61K9/0075 , A61K31/40 , C07D233/60

25. 发明公开

EP2980072A4 PHENYL DERIVATIVE 有权
标题翻译： PHENYLDERIVAT
公开(公告)号：EP2980072A4
公开(公告)日：2016-11-23
申请号：EP14775353
申请日：2014-03-25
申请人： ONO PHARMACEUTICAL CO
发明人： KUSUMI KENSUKE , NAGANAWA ATSUSHI , OTSUKI KAZUHIRO , SEKIGUCHI TETSUYA , SHINOZAKI KOJI , YAMAMOTO HIROSHI , YAMAMOTO YASUKO
IPC分类号： C07D207/12 , A61K31/40 , A61K31/451 , A61P1/16 , A61P3/06 , A61P3/10 , A61P9/00 , A61P9/04 , A61P9/06 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/00 , A61P13/12 , A61P17/02 , A61P19/02 , A61P25/00 , A61P25/04 , A61P27/02 , A61P27/06
CPC分类号： C07D211/52 , C07D207/12 , C07D211/44 , C07D211/48
摘要： An object of the present invention is to provide a compound having strong human S1P 2 antagonistic activity in order to develop a useful medicament for therapy of a S1P 2 -mediated disease such as a disease resulting from vascular constriction, fibrosis and respiratory disease. The compound represented by the general formula (I): wherein all the symbols have the same meanings as described in the specification, has a halogen atom or a haloalkyl group and a phenoxy group at certain substitution sites, and thus has strong human S1P 2 antagonistic activity. Therefore, the compound can be a therapeutic agent for a S1P 2 -mediated disease, such as a disease resulting from vascular constriction, fibrosis and respiratory disease.

26. 发明公开

EP3092229A1 PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS 失效
标题翻译： DOREN VERWENDUNG ALS ROR-GAMMA-MODULATOREN中的吡咯烷酮
公开(公告)号：EP3092229A1
公开(公告)日：2016-11-16
申请号：EP15700613.1
申请日：2015-01-05
申请人： Bristol-Myers Squibb Company
发明人： DUAN, Jingwu , DHAR, T.G. Murali , JIANG, Bin , LU, Zhonghui , XIAO, Hai-Yun
IPC分类号： C07D403/12 , C07D401/14 , C07D413/14 , C07D401/12 , C07D403/04 , C07D407/12 , C07D407/14 , C07D413/12 , C07D417/14 , C07D471/10 , C07D487/04 , C07D487/10 , C07D207/12 , C07D405/12 , C07D409/12
CPC分类号： C07D207/12 , C07D207/16 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/06 , C07D405/12 , C07D407/12 , C07D407/14 , C07D409/12 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/10 , C07D493/04 , C07D493/08
摘要： Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.
摘要翻译：描述了式（I）的RORγ调节剂或其立体异构体，互变异构体，药学上可接受的盐，溶剂合物或前药，其中所有取代基均在本文中定义。还提供了包含其的药物组合物。这样的化合物和组合物可用于调节细胞中RORγ活性的方法和用于治疗受试者治疗受益于RORγ活性例如自身免疫和/或炎性疾病的疾病或障碍的受试者的方法。

27. 发明公开

EP3083579A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS 有权
标题翻译：脂质和脂质组合物技术输送剂
公开(公告)号：EP3083579A1
公开(公告)日：2016-10-26
申请号：EP14827644.7
申请日：2014-12-17
申请人： Novartis AG
发明人： BRITO, Luis , CHEN, Delai , GAMBER, Gabriel Grant , GEALL, Andrew , LOVE, Kevin , ZABAWA, Thomas , ZECRI, Frederic
IPC分类号： C07D319/06 , C07D233/60 , C07C219/06 , C07C229/12 , C07D207/12 , C07D207/16 , C07D211/22 , C07D295/088 , C07D211/62 , A61K31/7088
CPC分类号： A61K9/5123 , A61K9/1272 , A61K31/7105 , A61K31/713 , A61K38/1816 , A61K38/2264 , A61K39/12 , A61K47/18 , A61K2039/53 , C07C219/06 , C07C219/16 , C07C229/12 , C07C235/08 , C07C323/52 , C07D207/12 , C07D207/16 , C07D211/06 , C07D211/22 , C07D211/46 , C07D211/62 , C07D233/60 , C07D233/64 , C07D295/088 , C07D295/13 , C07D319/06 , C12N7/00 , C12N15/1137 , C12N15/88 , C12N2310/14 , C12N2320/32 , C12N2760/00034 , C12N2760/00071
摘要： This invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R3, n, p, L1 and L2 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

28. 发明公开

EP3009123A1 MELANIN PRODUCTION INHIBITOR 审中-公开
标题翻译： MELANINPRODUKTIONSHEMMER
公开(公告)号：EP3009123A1
公开(公告)日：2016-04-20
申请号：EP15198370.7
申请日：2009-12-22
申请人： Pola Chemical Industries Inc.
发明人： Yokoyama, Kouji , Kimura, Makoto , Tamai, Masashi , Saitoh, Yuko , Kato, Tomomi , Ikeda, Yu
IPC分类号： A61K8/34 , A61K8/41 , A61K8/44 , A61K8/49 , A61Q19/02 , C07D233/58 , C07D401/06 , C07D207/12 , C07D207/404 , C07D295/03 , C07D295/096 , C07D213/30 , C07D213/38 , A61K8/46
CPC分类号： A61K8/4946 , A61K8/31 , A61K8/34 , A61K8/41 , A61K8/411 , A61K8/418 , A61K8/44 , A61K8/46 , A61K8/49 , A61K8/4913 , A61K8/4926 , A61K8/494 , A61K2800/74 , A61Q19/02 , C07D207/12 , C07D207/404 , C07D213/30 , C07D213/38 , C07D233/58 , C07D295/03 , C07D295/096 , C07D401/06
摘要： Disclosed is a melanin production inhibitor which has an excellent inhibitory activity on the production of melanin and is highly safe. The melanin production inhibitor comprises a compound represented by general formula (1) (excluding clotrimazole) and/or a pharmacologically acceptable salt thereof. In the formula, A1, A2 and A3 are independently selected from a hydrogen atom, an aryl group which may have a substituent, and an aromatic heterocyclic group which may have a substituent, wherein at least one of A1, A2 andA3 is selected from the aryl group and the aromatic heterocyclic group, the total number of carbon atoms contained in A1, A2 and A3 is 6 to 50 and, when at least two of A1, A2 and A3 represent the aryl groups or the aromatic heterocyclic groups, the adjacent two aryl or aromatic heterocyclic groups may be bound to each other via an alkyl chain or an alkenyl chain to form a ring; m represents an integer of 0 to 2; X represents a hetero atom, a hydrogen atom, or a carbon atom; R1 and R2 are independently selected from a hydrogen atom and an oxo group, wherein when one of R1 and R2 is an oxo group, the other is not present; and R3 is selected from a hydrogen atom, and a C 1-8 hydrocarbon group in which one or some of hydrogen atoms or carbon atoms may be substituted by a hetero atom or hetero atoms, wherein the number of R3's present in the compound corresponds to the number of X's and, when two or more R3's are present, the R3's are independently present and the adjacent two R3's may be bound to each other to form, together with X, a ring, and the terminal of R3 may be bound to a carbon atom to which A1, A2 and A3 are bound, thereby forming a ring.
摘要翻译：公开了对黑色素生成具有优异的抑制活性的黑色素生成抑制剂，是高度安全的。黑色素生成抑制剂包含通式（1）表示的化合物（克霉唑除外）和/或其药理学上可接受的盐。在该式中，A1，A2和A3独立地选自氢原子，可以具有取代基的芳基和可以具有取代基的芳族杂环基，其中A1，A2和A3中的至少一个选自芳基和芳香族杂环基时，A1，A2，A3中含有的碳原子总数为6〜50，A1，A2，A3中的至少2个表示芳基或芳香族杂环基时，芳基或芳族杂环基可以通过烷基链或烯基链彼此结合形成环; m表示0〜2的整数， X表示杂原子，氢原子或碳原子; R 1和R 2独立地选自氢原子和氧代基，其中当R 1和R 2之一是氧代基时，另一个不存在; 和R3选自氢原子和其中一个或一些氢原子或碳原子可以被杂原子或杂原子取代的C 1-8烃基，其中存在于化合物中的R3的数目对应于 X的数目，当存在两个或更多个R3时，R3独立地存在，并且相邻的两个R 3可以彼此结合形成与X一起形成环，并且R 3的末端可以被结合到与A1，A2和A3结合的碳原子，从而形成环。

29. 发明公开

EP2997024A1 PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF 有权
标题翻译：吡咯烷，药物组合物及其用途
公开(公告)号：EP2997024A1
公开(公告)日：2016-03-23
申请号：EP14723421.5
申请日：2014-05-09
申请人： Boehringer Ingelheim International GmbH
发明人： HEINE, Niklas , FLECK, Martin , NOSSE, Bernd , ROTH, Gerald Juergen
IPC分类号： C07D413/14 , A61K31/41 , C07D403/04 , C07D403/14 , C07D417/14 , C07D207/12 , A61P3/00
CPC分类号： C07D403/04 , C07D207/12 , C07D401/04 , C07D403/14 , C07D413/14 , C07D417/14
摘要： Pyrrolidine derivatives which are inhibitors of acetyl-CoA carboxylase(s) and their use in the treatment of obesity and type-2 diabetes. An exemplary compound is 2-(4-(1-[5-Chloro-6-(2-hydroxy-2-methyl-propoxy)-pyrimidin-4-yl]-(R)-pyrrolidin-3-yloxy)-phenyl)-N-cyclopropyl-propionamide.

30. 发明公开

EP2974724A1 PYRROLIDINE TRIPLE REUPTAKE INHIBITORS 审中-公开
标题翻译： DREIFACH吡咯烷 - 五羟色胺WIEDERAUFNAHME-INHIBITOREN
公开(公告)号：EP2974724A1
公开(公告)日：2016-01-20
申请号：EP15182162.6
申请日：2010-02-05
申请人： Sunovion Pharmaceuticals Inc.
发明人： SHAO, Liming , MA, Jianguo
IPC分类号： A61K31/40 , A61P25/24 , C07D405/04 , C07D207/06 , C07D207/08 , C07D207/12
CPC分类号： C07D207/06 , A61K31/40 , C07D207/08 , C07D207/12 , C07D405/04
摘要： In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
摘要翻译：在各种实施方案中，本发明提供环烷基吡咯烷化合物及其用于治疗和/或预防各种疾病，病症和综合征的方法，包括中枢神经系统（CNS）障碍，例如抑郁症，焦虑症，精神分裂症和睡眠障碍以及它们的合成方法。本发明还涉及含有本发明化合物的药物组合物，以及抑制来自突触裂缝的内源性单胺如多巴胺，5-羟色胺和去甲肾上腺素的再摄取的方法以及调节一种或多种单胺转运蛋白的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式